Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 184

1.

Intradermal or sublingual delivery and heat-labile enterotoxin (LT) proteins shape immunologic outcomes to CFA/I fimbriae-derived subunit antigen vaccine against enterotoxigenic E. coli.

Maciel M Jr, Bauer D, Baudier RL, Bitoun J, Clements JD, Poole ST, Smith MA, Kaminski RW, Savarino SJ, Norton EB.

Infect Immun. 2019 Aug 19. pii: IAI.00460-19. doi: 10.1128/IAI.00460-19. [Epub ahead of print]

PMID:
31427449
2.

Live attenuated enterotoxigenic Escherichia coli (ETEC) vaccine with dmLT adjuvant protects human volunteers against virulent experimental ETEC challenge.

Harro C, Louis Bourgeois A, Sack D, Walker R, DeNearing B, Brubaker J, Maier N, Fix A, Dally L, Chakraborty S, Clements JD, Saunders I, Darsley MJ.

Vaccine. 2019 Mar 28;37(14):1978-1986. doi: 10.1016/j.vaccine.2019.02.025. Epub 2019 Feb 21.

3.

HIV-1 vaccination by needle-free oral injection induces strong mucosal immunity and protects against SHIV challenge.

Jones AT, Shen X, Walter KL, LaBranche CC, Wyatt LS, Tomaras GD, Montefiori DC, Moss B, Barouch DH, Clements JD, Kozlowski PA, Varadarajan R, Amara RR.

Nat Commun. 2019 Feb 18;10(1):798. doi: 10.1038/s41467-019-08739-4.

4.

Exposure-response analysis of blinatumomab in patients with relapsed/refractory acute lymphoblastic leukaemia and comparison with standard of care chemotherapy.

Kuchimanchi M, Zhu M, Clements JD, Doshi S.

Br J Clin Pharmacol. 2019 Apr;85(4):807-817. doi: 10.1111/bcp.13864. Epub 2019 Feb 18.

5.

Intradermal vaccination with a Pseudomonas aeruginosa vaccine adjuvanted with a mutant bacterial ADP-ribosylating enterotoxin protects against acute pneumonia.

Baker SM, Pociask D, Clements JD, McLachlan JB, Morici LA.

Vaccine. 2019 Feb 4;37(6):808-816. doi: 10.1016/j.vaccine.2018.12.053. Epub 2019 Jan 9.

PMID:
30638799
6.

Receiver Operating Characteristic Analysis and Clinical Trial Simulation to Inform Dose Titration Decisions.

Clements JD, Perez Ruixo JJ, Gibbs JP, Doshi S, Perez Ruixo C, Melhem M.

CPT Pharmacometrics Syst Pharmacol. 2018 Nov;7(11):771-779. doi: 10.1002/psp4.12354. Epub 2018 Oct 15.

7.

The Mucosal Vaccine Adjuvant LT(R192G/L211A) or dmLT.

Clements JD, Norton EB.

mSphere. 2018 Jul 25;3(4). pii: e00215-18. doi: 10.1128/mSphere.00215-18. Review.

8.

Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+ T cells following parenteral immunization.

Frederick DR, Goggins JA, Sabbagh LM, Freytag LC, Clements JD, McLachlan JB.

Mucosal Immunol. 2018 Mar;11(2):549-561. doi: 10.1038/mi.2017.70. Epub 2017 Aug 9.

9.

Transcutaneous Immunization with a Band-Aid Prevents Experimental Otitis Media in a Polymicrobial Model.

Novotny LA, Clements JD, Goodman SD, Bakaletz LO.

Clin Vaccine Immunol. 2017 Jun 5;24(6). pii: e00563-16. doi: 10.1128/CVI.00563-16. Print 2017 Jun.

10.

Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses.

Clements JD, Freytag LC.

Clin Vaccine Immunol. 2016 Jun 6;23(6):438-441. doi: 10.1128/CVI.00214-16. Print 2016 Jun.

11.

Towards Rational Design of a Toxoid Vaccine against the Heat-Stable Toxin of Escherichia coli.

Taxt AM, Diaz Y, Aasland R, Clements JD, Nataro JP, Sommerfelt H, Puntervoll P.

Infect Immun. 2016 Mar 24;84(4):1239-1249. doi: 10.1128/IAI.01225-15. Print 2016 Apr.

12.

Evaluating the A-Subunit of the Heat-Labile Toxin (LT) As an Immunogen and a Protective Antigen Against Enterotoxigenic Escherichia coli (ETEC).

Norton EB, Branco LM, Clements JD.

PLoS One. 2015 Aug 25;10(8):e0136302. doi: 10.1371/journal.pone.0136302. eCollection 2015. Erratum in: PLoS One. 2015;10(9):e0138938.

13.

Therapeutic Transcutaneous Immunization with a Band-Aid Vaccine Resolves Experimental Otitis Media.

Novotny LA, Clements JD, Bakaletz LO.

Clin Vaccine Immunol. 2015 Aug;22(8):867-74. doi: 10.1128/CVI.00090-15. Epub 2015 May 27.

14.

The novel adjuvant dmLT promotes dose sparing, mucosal immunity and longevity of antibody responses to the inactivated polio vaccine in a murine model.

Norton EB, Bauer DL, Weldon WC, Oberste MS, Lawson LB, Clements JD.

Vaccine. 2015 Apr 15;33(16):1909-15. doi: 10.1016/j.vaccine.2015.02.069. Epub 2015 Mar 9.

15.

Serum and mucosal antibody responses to inactivated polio vaccine after sublingual immunization using a thermoresponsive gel delivery system.

White JA, Blum JS, Hosken NA, Marshak JO, Duncan L, Zhu C, Norton EB, Clements JD, Koelle DM, Chen D, Weldon WC, Oberste MS, Lal M.

Hum Vaccin Immunother. 2014;10(12):3611-21. doi: 10.4161/hv.32253.

16.

Impact of detergent on biophysical properties and immune response of the IpaDB fusion protein, a candidate subunit vaccine against Shigella species.

Chen X, Choudhari SP, Martinez-Becerra FJ, Kim JH, Dickenson NE, Toth RT 4th, Joshi SB, Greenwood JC 2nd, Clements JD, Picking WD, Middaugh CR, Picking WL.

Infect Immun. 2015 Jan;83(1):292-9. doi: 10.1128/IAI.02457-14. Epub 2014 Nov 3.

17.

Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells.

Read LT, Hahn RW, Thompson CC, Bauer DL, Norton EB, Clements JD.

Infect Immun. 2014 Dec;82(12):5308-16. doi: 10.1128/IAI.02496-14. Epub 2014 Oct 6.

18.

Characterization of heat-stable (STa) toxoids of enterotoxigenic Escherichia coli fused to double mutant heat-labile toxin peptide in inducing neutralizing Anti-STa antibodies.

Ruan X, Robertson DC, Nataro JP, Clements JD, Zhang W; STa Toxoid Vaccine Consortium Group.

Infect Immun. 2014 May;82(5):1823-32. doi: 10.1128/IAI.01394-13. Epub 2014 Feb 18.

19.

Evaluation in mice of a conjugate vaccine for cholera made from Vibrio cholerae O1 (Ogawa) O-specific polysaccharide.

Alam MM, Bufano MK, Xu P, Kalsy A, Yu Y, Freeman YW, Sultana T, Rashu MR, Desai I, Eckhoff G, Leung DT, Charles RC, LaRocque RC, Harris JB, Clements JD, Calderwood SB, Qadri F, Vann WF, Kováč P, Ryan ET.

PLoS Negl Trop Dis. 2014 Feb 6;8(2):e2683. doi: 10.1371/journal.pntd.0002683. eCollection 2014 Feb.

20.

Engaging actively with issues in the responsible conduct of science: lessons from international efforts are relevant for undergraduate education in the United States.

Clements JD, Connell ND, Dirks C, El-Faham M, Hay A, Heitman E, Stith JH, Bond EC, Colwell RR, Anestidou L, Husbands JL, Labov JB.

CBE Life Sci Educ. 2013 Winter;12(4):596-603. doi: 10.1187/cbe.13-09-0184.

21.

Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Martinez-Becerra FJ, Chen X, Dickenson NE, Choudhari SP, Harrison K, Clements JD, Picking WD, Van De Verg LL, Walker RI, Picking WL.

Infect Immun. 2013 Dec;81(12):4470-7. doi: 10.1128/IAI.00859-13. Epub 2013 Sep 23.

22.

Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD.

Heine SJ, Diaz-McNair J, Martinez-Becerra FJ, Choudhari SP, Clements JD, Picking WL, Pasetti MF.

Vaccine. 2013 Jun 19;31(28):2919-29. doi: 10.1016/j.vaccine.2013.04.045. Epub 2013 May 2.

23.

The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.

Leach S, Clements JD, Kaim J, Lundgren A.

PLoS One. 2012;7(12):e51718. doi: 10.1371/journal.pone.0051718. Epub 2012 Dec 20.

24.

Mesenchymal stem cells as a novel vaccine platform.

Tomchuck SL, Norton EB, Garry RF, Bunnell BA, Morris CA, Freytag LC, Clements JD.

Front Cell Infect Microbiol. 2012 Nov 16;2:140. doi: 10.3389/fcimb.2012.00140. eCollection 2012.

25.
26.

Antigen-specific memory T cell responses after vaccination with an oral killed cholera vaccine in Bangladeshi children and comparison to responses in patients with naturally acquired cholera.

Arifuzzaman M, Rashu R, Leung DT, Hosen MI, Bhuiyan TR, Bhuiyan MS, Rahman MA, Khanam F, Saha A, Charles RC, LaRocque RC, Weil AA, Clements JD, Holmes RK, Calderwood SB, Harris JB, Ryan ET, Qadri F.

Clin Vaccine Immunol. 2012 Aug;19(8):1304-11. doi: 10.1128/CVI.00196-12. Epub 2012 Jun 27.

27.

The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.

Norton EB, Lawson LB, Mahdi Z, Freytag LC, Clements JD.

Infect Immun. 2012 Jul;80(7):2426-35. doi: 10.1128/IAI.00181-12. Epub 2012 Apr 23.

28.

Mucosal immune responses induced by transcutaneous vaccines.

Lawson LB, Clements JD, Freytag LC.

Curr Top Microbiol Immunol. 2012;354:19-37. Review.

PMID:
22435116
29.

Bioencapsulation of the hepatitis B surface antigen and its use as an effective oral immunogen.

Hayden CA, Streatfield SJ, Lamphear BJ, Fake GM, Keener TK, Walker JH, Clements JD, Turner DD, Tizard IR, Howard JA.

Vaccine. 2012 Apr 19;30(19):2937-42. doi: 10.1016/j.vaccine.2012.02.072. Epub 2012 Mar 8.

30.

Transcutaneous immunization with a Vibrio cholerae O1 Ogawa synthetic hexasaccharide conjugate following oral whole-cell cholera vaccination boosts vibriocidal responses and induces protective immunity in mice.

Tarique AA, Kalsy A, Arifuzzaman M, Rollins SM, Charles RC, Leung DT, Harris JB, Larocque RC, Sheikh A, Bhuiyan MS, Saksena R, Clements JD, Calderwood SB, Qadri F, Kovác P, Ryan ET.

Clin Vaccine Immunol. 2012 Apr;19(4):594-602. doi: 10.1128/CVI.05689-11. Epub 2012 Feb 22.

31.

Broadly protective Shigella vaccine based on type III secretion apparatus proteins.

Martinez-Becerra FJ, Kissmann JM, Diaz-McNair J, Choudhari SP, Quick AM, Mellado-Sanchez G, Clements JD, Pasetti MF, Picking WL.

Infect Immun. 2012 Mar;80(3):1222-31. doi: 10.1128/IAI.06174-11. Epub 2011 Dec 27.

32.

Drug-disease interaction: Crohn's disease elevates verapamil plasma concentrations but reduces response to the drug proportional to disease activity.

Sanaee F, Clements JD, Waugh AW, Fedorak RN, Lewanczuk R, Jamali F.

Br J Clin Pharmacol. 2011 Nov;72(5):787-97. doi: 10.1111/j.1365-2125.2011.04019.x.

33.

Defending the mucosa: adjuvant and carrier formulations for mucosal immunity.

Lawson LB, Norton EB, Clements JD.

Curr Opin Immunol. 2011 Jun;23(3):414-20. doi: 10.1016/j.coi.2011.03.009. Epub 2011 Apr 19. Review.

PMID:
21511452
34.

Induction of increased permeability of polarized enterocyte monolayers by enterotoxigenic Escherichia coli heat-labile enterotoxin.

Kreisberg RB, Harper J, Strauman MC, Marohn M, Clements JD, Nataro JP.

Am J Trop Med Hyg. 2011 Mar;84(3):451-5. doi: 10.4269/ajtmh.2011.10-0445.

35.

Transcutaneous immunization as preventative and therapeutic regimens to protect against experimental otitis media due to nontypeable Haemophilus influenzae.

Novotny LA, Clements JD, Bakaletz LO.

Mucosal Immunol. 2011 Jul;4(4):456-67. doi: 10.1038/mi.2011.6. Epub 2011 Feb 16. Erratum in: Mucosal Immunol. 2012 Jan;5(1):110.

36.

Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant.

Norton EB, Lawson LB, Freytag LC, Clements JD.

Clin Vaccine Immunol. 2011 Apr;18(4):546-51. doi: 10.1128/CVI.00538-10. Epub 2011 Feb 2.

37.

Development of a Bacillus subtilis-based rotavirus vaccine.

Lee S, Belitsky BR, Brinker JP, Kerstein KO, Brown DW, Clements JD, Keusch GT, Tzipori S, Sonenshein AL, Herrmann JE.

Clin Vaccine Immunol. 2010 Nov;17(11):1647-55. doi: 10.1128/CVI.00135-10. Epub 2010 Sep 1.

38.

Unexpected modulation of recall B and T cell responses after immunization with rotavirus-like particles in the presence of LT-R192G.

Thiam F, Martino CD, Bon F, Charpilienne A, Cachia C, Poncet D, Clements JD, Basset C, Kohli E.

Toxins (Basel). 2010 Aug;2(8):2007-27. doi: 10.3390/toxins2082007. Epub 2010 Aug 5.

39.

Cholera-like enterotoxins and Regulatory T cells.

Basset C, Thiam F, Martino CD, Holton J, Clements JD, Kohli E.

Toxins (Basel). 2010 Jul;2(7):1774-95. doi: 10.3390/toxins2071774. Epub 2010 Jul 6. Review.

40.

Options for inactivation, adjuvant, and route of topical administration of a killed, unencapsulated pneumococcal whole-cell vaccine.

Lu YJ, Yadav P, Clements JD, Forte S, Srivastava A, Thompson CM, Seid R, Look J, Alderson M, Tate A, Maisonneuve JF, Robertson G, Anderson PW, Malley R.

Clin Vaccine Immunol. 2010 Jun;17(6):1005-12. doi: 10.1128/CVI.00036-10. Epub 2010 Apr 28.

41.

Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans.

Tribble DR, Baqar S, Scott DA, Oplinger ML, Trespalacios F, Rollins D, Walker RI, Clements JD, Walz S, Gibbs P, Burg EF 3rd, Moran AP, Applebee L, Bourgeois AL.

Infect Immun. 2010 Apr;78(4):1750-9. doi: 10.1128/IAI.01021-09. Epub 2010 Jan 19.

42.
43.

Prophylactic administration of bacterially derived immunomodulators improves the outcome of influenza virus infection in a murine model.

Norton EB, Clements JD, Voss TG, Cárdenas-Freytag L.

J Virol. 2010 Mar;84(6):2983-95. doi: 10.1128/JVI.01805-09. Epub 2010 Jan 6.

44.

Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.

Summerton NA, Welch RW, Bondoc L, Yang HH, Pleune B, Ramachandran N, Harris AM, Bland D, Jackson WJ, Park S, Clements JD, Nabors GS.

Vaccine. 2010 Feb 3;28(5):1404-11. doi: 10.1016/j.vaccine.2009.10.147. Epub 2009 Nov 6.

45.

Automated threshold detection for auditory brainstem responses: comparison with visual estimation in a stem cell transplantation study.

Bogaerts S, Clements JD, Sullivan JM, Oleskevich S.

BMC Neurosci. 2009 Aug 26;10:104. doi: 10.1186/1471-2202-10-104.

46.
47.

Kinetics of immune responses to influenza virus-like particles and dose-dependence of protection with a single vaccination.

Quan FS, Yoo DG, Song JM, Clements JD, Compans RW, Kang SM.

J Virol. 2009 May;83(9):4489-97. doi: 10.1128/JVI.02035-08. Epub 2009 Feb 11.

48.

IFN-gamma is the only anti-rotavirus cytokine found after in vitro stimulation of memory CD4+ T cells from mice immunized with a chimeric VP6 protein.

McNeal MM, Stone SC, Basu M, Clements JD, Choi AH, Ward RL.

Viral Immunol. 2007 Dec;20(4):571-84.

PMID:
18158731
49.

Use of nanocarriers for transdermal vaccine delivery.

Lawson LB, Freytag LC, Clements JD.

Clin Pharmacol Ther. 2007 Dec;82(6):641-3.

PMID:
17998911
50.

Effect of adjuvants and route of immunizations on the immune response to recombinant plague antigens.

Uddowla S, Freytag LC, Clements JD.

Vaccine. 2007 Nov 19;25(47):7984-93. Epub 2007 Oct 2.

Supplemental Content

Loading ...
Support Center